Polypill treatments for cardiovascular diseases

Expert Opinion on Drug Delivery

Volumn 13, Issue 1, 2016, Pages 1-6

  Webster, Ruth ^a   Rodgers, Anthony ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cardiovascular disease; cardiovascular prevention; fixed dose combination; polypills

Indexed keywords

ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; DRUG COMBINATION; ECONOMICS; HUMAN; RISK FACTOR;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 84955189857     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1111869     Document Type: Review

References (18)

1. Papers of special note have been highlighted as
2. either of interest (•) or of considerable interest
3. (••) to readers
4. Baigent C, Keech A, Kearney PM., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-Analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366 (9493): 1267-1278
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665
6. Baigent C, Blackwell L, Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-Analysis of individual participant data from randomised trials. Lancet. 2009; 373 (9678): 1849-1860
7. Yusuf S, Islam S, Chow CK., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011; 378 (9798): 1231-1243
8. World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. Geneva: World Health Organization; 2002 August 1-3
9. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326 (7404): 1419
10. Indian Polycap Study, Yusuf S, Pais P., et al. Effects of a polypill (Polycap) on risk factors in middle-Aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. [see comment]. Lancet. 2009; 373 (9672): 1341-1351
11. Malekzadeh F, Marshall T, Pourshams A., et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (polypill) on cardiovascular risk factors. Int J Clin Pract. 2010; 64 (9): 1220-1227
12. Pill Collaborative Group, Rodgers A, Patel A., et al. An international randomised placebo-controlled trial of a four-component combination pill (polypill) in people with raised cardiovascular risk. Plos One. 2011; 6 (5): e19857
13. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012; 7 (7): e41297
14. Yusuf S, Pais P, Sigamani A., et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Quality Outcomes. 2012; 5 (4): 463-471
15. Castellano JM, Sanz G, Penalvo JL., et al. A polypill strategy to improve adherence: results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project. J Am Coll Cardiol. 2014;64(20):2071-2082
16. Thom S, Poulter N, Field J., et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013; 310 (9): 918-929
17. Patel A, Cass A, Peiris D., et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920-930
18. Selak V, Elley CR, Bullen C., et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014; 348:g3318